Stock Market

Market Volatility Reaches Historic Levels as Tariff Tensions Escalate

Published

11 months ago

April 11, 2025

The stock market is experiencing one of its most volatile weeks in history as investors grapple with escalating trade tensions and tariff uncertainties. Wall Street has been on a rollercoaster ride, with dramatic swings that have left even seasoned investors struggling to keep pace with rapidly changing market conditions.

Unprecedented Market Swings

This week has marked one of the most turbulent periods on record for Wall Street. The S&P 500 tumbled 3.46% on Thursday, while the Dow Jones Industrial Average plummeted 1,014.79 points, or 2.5%. The technology-heavy Nasdaq Composite was hit particularly hard, ending Thursday down 4.31%. These losses came just one day after an extraordinary rally on Wednesday, when the S&P 500 surged 9.52% – its third-largest single-day gain since World War II – while the Dow skyrocketed more than 2,900 points.

The CBOE Volatility Index, commonly known as the VIX or “fear gauge,” spiked above 50 earlier in the week, reflecting extreme market uncertainty. For context, the VIX typically hovers between 15 and 20 during normal market conditions, with readings above 30 generally indicating significant anxiety among investors.

Tariff Tensions at the Center of Market Turmoil

At the heart of this market volatility lies escalating trade tensions between the United States and its global trading partners, particularly China. The Trump administration has implemented a universal tariff rate of 10% on most imports, with a striking exception for Chinese goods, which now face a staggering 145% duty.

China wasted no time in retaliating, announcing on Friday that it would raise its levies on U.S. products to 125% from the previous 84%. In a strongly worded statement, the Chinese finance ministry declared, “Even if the U.S. continues to impose higher tariffs, it will no longer make economic sense and will become a joke in the history of world economy.”

The European Union has also entered the fray, with its trade representative scheduled to fly to Washington on Sunday in an attempt to “try and sign deals” that might mitigate the impact of these tariffs on European exports.

Current Tariff Landscape

The current U.S. tariff structure now includes:

145% duty on all goods from China
25% tariffs targeting aluminum, automobiles, and goods from Canada and Mexico not covered under the United States-Mexico-Canada Agreement
10% levy on all other imports

This complex tariff environment has created significant uncertainty for businesses, consumers, and investors alike. As Jed Ellerbroek, portfolio manager at Argent Capital Management, noted, “The lower tariff level is still a huge problem, and deadlines three months out offer no certainty for consumers, business, and investors. This set of policies will leave the U.S. with higher inflation, lower economic growth, and a frustrated stock market.”

Impact on Global Markets

The tariff tensions have reverberated beyond U.S. borders, disrupting global markets and financial systems. According to Reuters, the turmoil in the wake of President Trump’s tariff hikes has abruptly stalled emerging market sovereign debt sales in April, after issuance from developing nations had been robust in previous months.

This disruption in the bond market highlights how trade policy uncertainty can quickly spread across different asset classes and geographic regions, creating a contagion effect that amplifies market volatility.

Market Performance Amid the Chaos

Despite the tumultuous week, the three major U.S. stock indices are on pace for solid gains in the period. The S&P 500 is tracking toward a 3.1% advance, its best weekly performance since November. The Nasdaq is on track to gain 4.7%, while the Dow is pacing for a 2.8% jump week to date.

However, these weekly gains must be viewed in the context of the broader market decline since April 2, when the White House first announced its reciprocal tariff plans. Since that announcement, the S&P 500 has fallen more than 7%, erasing a significant portion of its year-to-date gains.

Notable Stock Movements

Amid the broader market volatility, individual stocks have experienced significant movements:

In the technology sector, NVIDIA Corporation (NVDA) has shown resilience, gaining 0.71% to trade at $108.33, while Intel Corporation (INTC) has struggled, falling 6.24% to $18.64. Tesla (TSLA) has managed a modest gain of 0.35%, trading at $253.29.

Among the top gainers, Zai Lab Limited (ZLAB) surged 17.06% to $28.47, while Kingsoft Cloud Holdings Limited (KC) climbed 8.84% to $13.72. On the losing side, Barry Callebaut AG (BRRLY) plummeted 19.88% to $10.32, and Texas Instruments Incorporated (TXN) dropped 9.19% to $142.21.

Expert Outlook and Investor Sentiment

Market experts remain divided on the long-term implications of the current trade tensions and market volatility. Some view the recent market swings as an overreaction that presents buying opportunities, particularly in fundamentally sound companies that have been caught in the broader market downdraft.

Others, however, caution that the uncertainty surrounding trade policy could continue to weigh on market sentiment and corporate earnings for the foreseeable future. The lack of clarity regarding how long these tariffs will remain in place and whether they might be increased further adds another layer of complexity to investment decisions.

Looking Ahead

As Wall Street wraps up one of its wildest weeks ever, investors are closely monitoring developments on the trade front. The upcoming meeting between EU trade representatives and U.S. officials could provide some clarity on the path forward, at least for transatlantic trade relations.

Market participants will also be watching for any signs of economic impact from the tariffs, particularly in upcoming inflation data and corporate earnings reports. Companies with significant exposure to international trade or global supply chains may face heightened scrutiny as investors assess the potential impact on their bottom lines.

In this environment of elevated uncertainty, market volatility is likely to remain high in the near term. Investors would be wise to maintain a diversified portfolio and avoid making impulsive decisions based on short-term market movements. As the old Wall Street adage goes, “Time in the market beats timing the market” – a principle that becomes even more relevant during periods of extreme volatility.

As financial markets navigate these choppy waters, one thing remains clear: the interconnectedness of the global economy means that trade policy decisions have far-reaching implications that extend well beyond national borders. The coming weeks will be crucial in determining whether the current market turbulence represents a temporary disruption or the beginning of a more prolonged period of economic uncertainty.

Stock Market

Hemostemix Revolutionizes Stem Cell Therapy Access with “Boots on the Ground” Strategy in Florida

Published

6 months ago

August 26, 2025

LUSSO'S NEWS

Hemostemix Inc., a clinical-stage biotechnology company, is making headlines today with a bold new initiative aimed at expanding access to its autologous stem cell therapy, VesCell™ (ACP-01), across Florida under the state’s compassionate-use framework.

What’s New Today?

“Boots on the ground” initiative launched in Florida
Hemostemix has officially rolled out a face-to-face sales and outreach program in Miami, Naples, and Tampa. Spearheaded by CEO Thomas Smeenk and CCO Croom Lawrence, the team is engaging directly with podiatrists, cardiologists, vascular surgeons, and former Phase II trial investigators to build awareness and facilitate adoption of VesCell™ in clinics statewide.

Why It Matters

1. Regulatory Pathway Utilization
Florida’s SB 1768 right-to-try law allows Hemostemix to offer VesCell™ to patients with life-threatening or severely debilitating conditions who have exhausted standard-of-care options. This innovative approach enables patients to access cutting-edge treatments while Hemostemix gathers real-world evidence to support future FDA submissions.

2. Substantive Clinical Evidence
By August 2025, Hemostemix has treated 498 patients, completed seven clinical studies involving 318 subjects, and published findings across 11 peer-reviewed journals—all reinforcing VesCell™’s safety and efficacy in treating conditions like CLTI, angina, and various cardiomyopathies.
Clinical highlights include dramatic ulcer healing (from 1.46 cm² down to 0.48 mm² in three months, p = 0.01), improved cardiac function, and enhanced patient comfort and mobility.

3. Building Clinical Partnerships
Hemostemix’s engagement model emphasizes relationship-building: they’re not just promoting a treatment—they’re collaborating with clinicians who are familiar with ACP-01 from the trials. The aim is to foster trust, streamline adoption, and ensure rigorous data collection for later regulatory interaction.

Broader Context: Strategy Meets Execution

Funding and Growth
Hemostemix has secured multiple rounds of financing, including a recent private placement, giving the company resources to drive commercialization in Florida and prepare for eventual FDA interaction.
Dual Purpose Rollout
The Florida initiative both generates revenue through compassionate-use treatments and builds a robust evidence base for regulators—reinforcing Hemostemix’s long-term strategy.

Suggested Headlines to Raise Awareness

Hemostemix Brings Stem Cell Therapy to Florida: “Boots on the Ground” Initiative Takes VesCell™ Directly to Clinics
Autologous Stem Cell Access in Action: Hemostemix Engages Florida Clinicians to Transform Care for No-Option Patients
From Trials to Treatment: Hemostemix’s On-the-Ground Strategy in Florida Sets Stage for Broader Approval

Why This Announcement Matters — In Short

Patients: Offers new hope to individuals with severe, otherwise untreatable conditions.
Clinicians: Provides direct access to a promising therapy and support for implementation.
Investors: Demonstrates tactical commercialization with regulatory foresight and clinical validation.
Industry: Signals a novel model for balancing compassionate use with evidence generation in biomedicine.

Sources

Hemostemix’s Boots on the Ground in Florida

Disclosure: Lusso’s News, LLC(“EMV”) has been compensated by Hemostemix Inc. (“Hemostemix”) in the amount of $5,000 USD per month, commencing August 13, 2025, and continuing through September 31, 2025, with the possibility of extension until further notice. This compensation is for the creation and dissemination of content about Hemostemix, including but not limited to articles, website postings, social media updates, and other promotional materials.

The content produced by EMV is intended solely for informational purposes. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any security, investment product, or trading strategy. EMV is not a registered investment adviser or broker-dealer, and nothing in this content should be construed as personalized investment advice.

Investing in securities involves risks, including the potential loss of principal. Readers should conduct their own independent research, perform due diligence, and consult with a licensed financial adviser, attorney, or tax professional before making any investment decisions.

EMV’s compensation from Hemostemix presents a conflict of interest as EMV has a financial incentive to promote Hemostemix. As a result, the content may be biased and should not be relied upon as independent or impartial.

By accessing this content or the associated website, you acknowledge and agree to the terms of this disclaimer.

Stock Market

Snow Lake Energy (NASDAQ: LITM) Uses X to Spotlight Its Uranium Push

Published

6 months ago

August 26, 2025

LUSSO'S NEWS

Welcome to the first of a series of video clips from our CEO.

The purposes of these clips are to give you:
✅In Depth Look at Snow Lake Energy
✅Our Strategy
✅Our Critical Minerals Projects
🚨 Global Events that will Help Shape the Future Of Snow Lake

NASDAQ: $LITM pic.twitter.com/WbZ1IxXROp
— Snow Lake Energy (@SnowLakeEnergy) August 21, 2025

Snow Lake Resources Ltd., operating as Snow Lake Energy (NASDAQ: LITM), is stepping up its investor engagement with a new video series on X, showcasing its uranium exploration projects and expanding role in the global clean energy transition.

The Canadian-based critical minerals explorer is using social media to pull back the curtain on its operations, giving investors an inside look at how it’s aligning with U.S. energy security priorities and tapping into surging demand for nuclear power to fuel AI-driven infrastructure.

A Strategic Pivot Toward Uranium

Snow Lake Energy has undergone a major pivot, shifting focus from lithium toward uranium — a move driven by tightening global energy markets and nuclear’s rising profile as a clean, base-load power source.

Pine Ridge Uranium Project (Wyoming): A 50/50 joint venture with Global Uranium & Enrichment Limited (GUE), strategically located in the Powder River Basin near Cameco’s Smith Ranch Mill, which processes up to 5.5 million pounds of U3O8 annually. Pine Ridge is advancing as an in-situ recovery (ISR) project with an aggressive 125,000-foot drill program set for 2025.
Engo Valley Project (Namibia): Early results are promising, and Phase 2 drilling (7,500 meters) is underway to build out a stronger resource model.

This uranium focus comes as the U.S. government accelerates domestic nuclear investment through four Nuclear Executive Orders signed in May 2025, aimed at rapidly expanding nuclear deployment to meet AI-related energy needs.

Investor Outreach Through Multimedia

The X video series is part of Snow Lake’s strategy to make complex exploration updates digestible and exciting for investors. The clips likely feature:

On-site footage from drill programs
Expert commentary from leadership
Visual data highlighting resource potential

By turning technical progress into compelling stories, Snow Lake is aiming to build momentum with both institutional and retail investors. CEO Frank Wheatley has repeatedly emphasized the company’s commitment to transparency and engagement, with the video rollout complementing frequent press releases and appearances at investor conferences such as ThinkEquity 2024.

Notably, Snow Lake has also partnered with Exodys Energy to create a new nuclear reactor development company focused on small modular reactors (SMRs), further solidifying its positioning in the clean energy sector.

Welcome to the 2nd video of a series of video clips from our CEO.

Discuss is our two pronged strategy:
1️⃣ Expand our footprint across the nuclear fuel cycle…

2️⃣ Expand both our portfolio of and investments in North America critical mineral projects

NASDAQ: $LITM pic.twitter.com/jAdowk2w1c
— Snow Lake Energy (@SnowLakeEnergy) August 25, 2025

Market Momentum and Investor Sentiment

The timing is crucial. Uranium prices have surged amid geopolitical pressures and global decarbonization policies, sparking renewed investor interest. Snow Lake’s own shares spiked more than 70% in December 2024 following a $15 million public offering at $0.80 per share to fund exploration.

Still, analysts remain cautious. Current ratings lean “hold,” citing negative returns on assets (-7.4%) and equity (-14.5%), even as sentiment around uranium builds. Snow Lake’s video series may be designed to counterbalance these headwinds by emphasizing long-term potential and policy tailwinds, especially with the U.S. targeting a quadrupling of nuclear power by 2050.

Outlook: Riding the Clean Energy Wave

With a market cap near $30.5 million (May 2025) and shares trading at $3.94, Snow Lake remains a speculative but ambitious small-cap. Its success depends on proving out Pine Ridge and Engo Valley while keeping investors engaged with visible progress.

By leaning on multimedia storytelling, Snow Lake is turning its corporate updates into a broader clean-energy narrative — one that investors tracking nuclear, AI power demand, and critical minerals will find increasingly hard to ignore.

As one X user recently put it, “Momentum is exploding for assets tied to the energy transition.” Snow Lake is clearly betting it can ride that wave.

👉 For more details, visit www.snowlakeenergy.com or follow @SnowLakeEnergy on X for the latest videos and corporate news.

Disclaimer

Lusso’s News, LLC (“we,” “our,” or “the Company”) has been compensated fifteen thousand U.S. dollars (USD $15,000) by a third party for investor awareness and media coverage related to Snow Lake Resources Ltd. (NASDAQ: LITM). This compensation is for a six-month period beginning June 2025 and ending December 2025.

The content provided by Lusso’s News, LLC, including but not limited to articles, videos, social media posts, and other media, is intended for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. We are not registered as a broker-dealer, investment advisor, or in any other capacity with the U.S. Securities and Exchange Commission (SEC) or any state securities authority.

This material may contain forward-looking statements, including projections, forecasts, estimates, and other information that is predictive in nature. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the control of Snow Lake Resources Ltd. or Lusso’s News, LLC, that could cause actual results to differ materially from those anticipated. Readers should not place undue reliance on such statements.

Investing in securities, particularly micro-cap and small-cap stocks, involves substantial risk, including the potential for total loss of principal. Always conduct your own independent research and consult with a licensed financial advisor before making any investment decisions.

Lusso’s News, LLC assumes no responsibility or liability for any investment decisions made based on the information we provide. By viewing our content, you acknowledge and agree to these terms.

Stock Market

Hemostemix: Florida Law Opens Door for Stem Cell Therapy Expansion

Published

7 months ago

August 14, 2025

LUSSO'S NEWS

On July 1, 2025, Florida enacted Senate Bill 1768, a landmark law allowing physicians to offer certain autologous stem cell therapies that are not yet FDA-approved, provided patients give informed consent and the procedures are conducted by licensed professionals.

This regulatory shift creates an immediate opportunity for Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF), a Canadian regenerative medicine company specializing in VesCell/ACP-01, a therapy designed to restore blood flow and promote healing in patients suffering from severe ischemia.

Why This Matters for Hemostemix

Hemostemix has already treated over 498 patients with ACP-01, showing trial results that include smaller ulcer sizes, improved circulation, and reduced amputation rates. With Florida’s new legal framework, the company can now commercialize VesCell in the Sunshine State before FDA approval—potentially accelerating both adoption and revenue. First treatments in Florida are targeted for late 2025, and Hemostemix projects $22.5 million in sales for 2026.

Learning from Other Biotech Breakouts

The biotech sector has a history of companies making exponential gains when innovation meets the right market conditions:

Exact Sciences rose from ~$2 in 2013 to over $130 at its peak on the success of its Cologuard cancer test.
Moderna was a relatively unknown small-cap before its mRNA platform propelled its COVID-19 vaccine to global use, driving shares from around $18 to nearly $500.
Vertex Pharmaceuticals climbed more than 1,000% over a decade by pioneering treatments for cystic fibrosis.
Regeneron surged over 600% on the blockbuster performance of its eye drug Eylea.
Novavax went from under $5 to over $300 during the race to produce a COVID-19 vaccine.

Each of these cases involved a scientific breakthrough meeting favorable timing—whether regulatory changes, urgent public health needs, or key clinical results.

The Road Ahead

It’s important to note that VesCell remains investigational, and investment in early-stage biotech carries significant risk. Florida’s new law does not imply FDA approval; rather, it creates a pathway for patients and physicians to access therapies under specific conditions.

For Hemostemix, this legal shift may represent a pivotal moment—much like other inflection points that helped propel biotech companies from obscurity to the forefront of their fields. Whether the company follows that trajectory will depend on clinical performance, market uptake, and investor confidence in the years ahead.

By accessing this content or the associated website, you acknowledge and agree to the terms of this disclaimer.